IMUX IMMUNIC INC revenue, earnings and financials
For the quarter ended June 30, 2026, IMMUNIC INC reported revenue of n/a, net income of −$34.1M and diluted EPS of −$0.80; for the fiscal year ended December 2025 revenue was n/a.
IMUX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$103M, net income −$97.2M (margin n/a), EPS −$0.62
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$98.1M, net income −$101M (margin n/a), EPS −$1.00
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$99.2M, net income −$93.6M (margin n/a), EPS −$2.11
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$119M, net income −$120M (margin n/a), EPS −$3.78
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$91.7M, net income −$92.9M (margin n/a), EPS −$3.93
IMUX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$34.1M, EPS −$0.80
- Quarter ended Mar 31, 2026: revenue n/a, net income −$32.6M, EPS −$1.08
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$19.3M, EPS $4.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$25.6M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue n/a, net income −$26.8M, EPS −$2.03
- Quarter ended Mar 31, 2025: revenue n/a, net income −$25.5M, EPS −$2.51
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$25.2M, EPS −$0.25
- Quarter ended Sep 30, 2024: revenue n/a, net income −$24.4M, EPS −$0.24
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.4M, EPS −$0.21
- Quarter ended Mar 31, 2024: revenue n/a, net income −$29.6M, EPS −$0.30
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$21.6M, EPS −$0.48
- Quarter ended Sep 30, 2023: revenue n/a, net income −$22.8M, EPS −$0.51
- Quarter ended Jun 30, 2023: revenue n/a, net income −$24.0M, EPS −$0.54
- Quarter ended Mar 31, 2023: revenue n/a, net income −$25.3M, EPS −$0.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$56.5M, EPS −$1.63
- Quarter ended Sep 30, 2022: revenue n/a, net income −$21.2M, EPS −$0.69
- Quarter ended Jun 30, 2022: revenue n/a, net income −$21.9M, EPS −$0.72
- Quarter ended Mar 31, 2022: revenue n/a, net income −$20.8M, EPS −$0.74
- Quarter ended Dec 31, 2021: revenue n/a, net income −$21.2M, EPS −$0.81
- Quarter ended Sep 30, 2021: revenue n/a, net income −$19.3M, EPS −$0.76
IMUX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$85.8M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$84.8M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$70.8M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$65.1M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow −$83.2M, share buybacks n/a, dividends $0.00 per share
IMUX balance sheet
- Jun 30, 2026: cash $155M, total assets $159M, total liabilities $31.6M, shareholders' equity $128M
- Mar 31, 2026: cash $187M, total assets $190M, total liabilities $38.5M, shareholders' equity $151M
- Dec 31, 2025: cash $15.5M, total assets $24.1M, total liabilities $30.7M, shareholders' equity −$6.67M
- Sep 30, 2025: cash $35.1M, total assets $40.7M, total liabilities $30.2M, shareholders' equity $10.5M
- Jun 30, 2025: cash $55.3M, total assets $61.4M, total liabilities $27.5M, shareholders' equity $33.9M
- Mar 31, 2025: cash $14.3M, total assets $20.5M, total liabilities $25.8M, shareholders' equity −$5.29M
- Dec 31, 2024: cash $35.7M, total assets $40.9M, total liabilities $22.4M, shareholders' equity $18.4M
- Sep 30, 2024: cash $59.1M, total assets $64.8M, total liabilities $23.5M, shareholders' equity $41.2M
Is IMUX profitable?
No. IMMUNIC INC lost $112M over the last four quarters.
What is IMUX's EPS?
Diluted earnings per share over the last four quarters were $2.04; −$0.80 in the latest quarter.